A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.
Clinical Trials Arena on MSN
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial"Intellia Therapeutics’ stock rocked by patient death in gene therapy trial" was originally created and published by Clinical ...
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who ...
The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, ...
Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.
The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback